About Regado

HISTORY OF REGADO

2003	Regado was founded in Durham, North Carolina

2004

Regado raised $5.6 million in a Series A financing from Aurora Funds (Durham, NC) and individual investors

2005

The Company completed its Series B funding round, raising $20 million, and added new investors Domain Associates (Princeton, NJ) and Quaker BioVentures (Philadelphia, PA)

Regado initiated its Phase 1 program for the REG1 Anticoagulation System, the first specific, direct-acting, anticoagulant aptamer-control agent pair ever described

2006

The Company completed its Phase 1a clinical study

The Company’s Phase 1a REG1 data were presented during a late breaker session at the 2006 American Heart Association (AHA) annual meeting

The REG1 Phase 1a data were published in Circulation

2007

The REG1 Phase 1b clinical study was completed

Regado completed the REG1 Phase 1c clinical study

Regado raised $23 million in a Series C round, adding Caxton to the Company’s list of investors

With the addition of a drug discovery team, the Company began development of Regado’s next-generation aptamer-control agent pairs

The clinical results from the REG1 Phase 1c study and the combined results from the Phase 1a and Phase 1b studies were presented in separate sessions during the 2007 American Heart Association’s annual meeting

2008

Regado’s REG1 Phase 1c data were published in The Journal of Haemostasis and Thrombosis

Circulation published Regado’s REG1 Phase 1b study results

Regado appointed David J. Mazzo, Ph.D., as President and Chief Executive Officer

Regado opened an headquarters in Basking Ridge, NJ

REG1 Phase 1a, 1b and 1c data presented at the European Society of Cardiology Congress

Regado completed enrollment in its REG1 Phase 2a study (REVERSAL-PCI)

2009

REVERSAL-PCI (REG1 phase 2a) were presented at the European Society of Cardiology Annual Meeting

The Company formed a Medical Advisory Board comprised of internationally renowned experts in cardiovascular medicine, interventional procedures and surgery and chairman by Dr. Robert Harrington of Duke University

A rigorous, adaptive design, phase 2b study of REG1 (RADAR trial) was initiated in the fall

A single escalating dose phase 1a study of the Company’s second product candidate (REG2) was completed. REG2 consists of a subcutaneously administered depot formulation of RB006 paired with an IV bolus formulation of RB007

The Company completed a series D funding round, raising $40 million and adding new investor, Edmond de Rothschild Investment Partners (Paris, France)